<DOC>
	<DOCNO>NCT03089658</DOCNO>
	<brief_summary>Expanded access Avelumab solution infusion make available adult patient mMCC whose disease progress receive least one prior chemotherapy .</brief_summary>
	<brief_title>Expanded Access Avelumab Treatment Metastatic Merkel Cell Carcinoma ( mMCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<criteria>Measurable metastatic Merkel cell carcinoma accord Response Evaluation Criteria In Solid Tumors version 1.1 ( RECIST v1.1 ) , fail least one line adequately dose chemotherapy metastatic set subsequently progress ( adequate dosing define minimum 2 cycle ) Not eligible participation ongoing clinical trial Merkel cell carcinoma include Javelin Merkel 200 study ( NCT02155647 ) Adequate hematological , hepatic renal function define protocol Brain metastases Prior organ transplantation , include allogeneic stem cell transplantation History test positive human immunodeficiency virus ( HIV ) know AIDS active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Concurrent , active , malignant disease ( Merkel cell carcinoma ) exception basal squamous cell carcinoma skin carcinoma situ define protocol Previous active autoimmune disease require systemic immunosuppressive therapy Known severe hypersensitivity reaction monoclonal antibody , history anaphylaxis , uncontrolled asthma Clinically significant ( , active ) cardiovascular disease : cerebral vascular accident / stroke ( &lt; 6 month prior enrollment ) , myocardial infarction ( &lt; 6 month prior enrollment ) unstable angina , congestive heart failure ( New York Heart Association Classification Class ≥ II ) , serious cardiac arrhythmia require medication Persisting toxicity relate prior therapy Grade &gt; 1 NCICTCAE v 4.03 ( alopecia sensory neuropathy Grade ≤ 2 acceptable ) Being treat chronic systemic corticosteroid chronic therapeutic immunosuppression Pregnant lactating ( woman childbearing potential ) Not use highly effective contraception risk conception exists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Merkel Cell Carcinoma</keyword>
	<keyword>Expanded Access Program</keyword>
	<keyword>Temporary Authorisation Use</keyword>
	<keyword>Avelumab</keyword>
</DOC>